Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones

VivoSim Labs, INC.

Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.
Upfront cash payment $10M; $9M paid at closing, $1M held in escrow for 15 months.
Potential milestone payments up to $50M contingent on development, regulatory, and commercial milestones.
Lilly assumes certain liabilities and will be responsible for all future clinical development of FXR314.
Director Vaidehi Joshi resigned March 21, 2025, effective immediately, with no disagreement with the Company.

item 2.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Vaidehi Joshi

Director

VIVS · VivoSim Labs, INC.

Effective: 2025-03-21
Filed: March 26, 2025, 7:59 PM ET

On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the "Board") of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Vaidehi Joshi resigned as Director at VivoSim Labs, INC..

Action: resigned
Role: Director

Exact text from the filing

On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the "Board") of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025.

View on SEC.gov

VivoSim Labs, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-044801

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.